| Expression pattern: |
UP |
| Associated gene: |
ASF1B, Cyclin D1, E-cad, Vimentin, Ki67 |
| Associated microRNA: |
miR-122-5p |
| Biological function: |
CircCDK17 acts as an oncogenic regulator in cervical cancer; its silencing inhibits CC cell proliferation, cell cycle progression, migration, invasion, and xenograft tumor growth. |
| Molecular mechanism: |
circCDK17 functions as a ceRNA that sponges miR-122-5p to post-transcriptionally regulate ASF1B expression, thereby modulating Cyclin D1, E-cad, and Vimentin and promoting cervical cancer progression. |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; EdU Staining; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
circCDK17 expression was associated with TNM grade, tumor size, lymph node metastasis, and HPV status; up-regulated circCDK17 may have potential value as a diagnostic marker in cervical cancer. |
| Description: |
circCDK17 is up-regulated in cervical cancer tissues and cells and functions as an oncogenic circRNA. It promotes proliferation, cell cycle progression, migration, invasion, and tumor growth by acting as a ceRNA for miR-122-5p and increasing ASF1B expression. Its expression is associated with clinicopathologic features and may have diagnostic or therapeutic relevance in cervical cancer. |
| Confidence score: |
0.8175 |